Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CCD-01535AC1-01 | Other Identifier | Chiesi Farmaceutici |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study.
Large non pharmacological studies on Small Airways Disease
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Asthmatic patients | asthmatic patients 18 to 65 | ||
| Healthy volunteers | Volunteers 18 to 65 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To determine the role of small airways abnormalities in the clinical manifestations of asthma. | 1 year |
Not provided
Not provided
Asthmatic patient inclusion criteria
Male or female patients aged ≥ 18 and ≤ 65 years, who have signed an Informed Consent form
Clinical diagnosis of asthma f
Patients with stable asthma.
Current smoker, ex-smoker or lifelong non-smoker Healthy subject inclusion criteria
1. Male or female patients aged ≥ 18 and ≤ 65 years 2. No clinical history of asthma or COPD 3. Current smoker, ex-smoker or lifelong non-smokers 4. Normal spirometry 5. Normal airways responsiveness Asthmatic patient exclusion criteria
1. Cigarette smoking history > 10 packyears 2. Diagnosed upper and/or lower respiratory disease(s). 3. Clinical or functional uncontrolled haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that mightp compromise the results or interpretation of the study.
4. Pregnant or lactating women 5. Participation in an interventional clinical trial <12 weeks preceding baseline visit 6. Inability to comply with study procedures. 7. Alcohol or drug abuse.
Not provided
Not provided
900 subjects divided into 800 asthmatic patients and 100 healthy controls will be included. Recruitment will be balanced, at the extent possible, in order to achieve at least > 150 patients each for steps 1 - 4 and > 50 patients for step 5 as indicated in the international guidelines (GINA 2012) on the basis of their previous therapy. The 150 healthy controls will be recruited on the basis of absence of respiratory symptoms, airway obstruction and hyper responsiveness.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Monica Kraft, MD | Duke University | Principal Investigator |
| Dirkje S Postma, Prof. Dr. | University Medical Center Groningen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chiesi Clinical Trial Site #0503 | Denver | Colorado | 80206 | United States | ||
| Chiesi Clinical Trial Site #0502 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30876830 | Result | Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med. 2019 May;7(5):402-416. doi: 10.1016/S2213-2600(19)30049-9. Epub 2019 Mar 12. | |
| 41038213 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Optional bronchoscopy with endobronchial and trans-bronchial biopsy will be applicable in selected sites only in EU and US. Total number of inflammatory cells and quantification of specific cells including eosinophils, T cells and macrophages will be performed. Gene expression profiles (including RNA) will be performed at a later date for future analysis on the pathobiology of asthma which will be defined in future specific protocols
| Durham |
| North Carolina |
| 27710 |
| United States |
| Chiesi Clinical Trial Site #0504 | Cleveland | Ohio | 44106 | United States |
| Chiesi Clinical Trial Site #0501 | Houston | Texas | 77030 | United States |
| Prof. Dr. Emilio Pizzichini | Florianópolis | Brazil |
| Prof. Dr. Alberto Cukier | São Paulo | Brazil |
| Prof. Dr. Rafael Stelmach | São Paulo | Brazil |
| Chiesi Clinical Trial Site #0201 | Montreal | Quebec | H2X 2P4 | Canada |
| Gao | Beijing | Beijing Municipality | 100730 | China |
| Yuanlin Song | Shanghai | Shanghai Municipality | 200032, | China |
| Qingling Zhang | Hangzhou | 510120 | China |
| Chiesi Clinical Trial Site #0303 | Großhansdorf | D-22927 | Germany |
| Chiesi Clinical Trial Site #0301 | Hanover | 30625 | Germany |
| Chiesi Clinical Trial Site #0302 | Leipzig | D-04357 | Germany |
| Chiesi Clinical Trial Site #0104 | Ferrara | 44124 | Italy |
| Chiesi Clinical Trial Site #0101 | Naples | Italy |
| Scichilone | Palermo | Italy |
| Chetta | Parma | Italy |
| Chiesi Clinical Trial Site #0103 | Pisa | 56124 | Italy |
| Chiesi Clinical Trial Site #0102 | Verona | 37134 | Italy |
| Dr. M. Broeders | 's-Hertogenbosch | Netherlands |
| W. Boersma | Alkmaar | Netherlands |
| Dr. J. Vroegop | Groningen | Netherlands |
| Dr. M. vd Berge | Groningen | Netherlands |
| Chiesi Clinical Trial Site #0402 | Barcelona | 08026 | Spain |
| Chiesi Clinical Trial Site #0401 | Lugo | 27003 | Spain |
| Derived |
| Galant SP, Kuks PJM, Kole TM, Kraft M, Siddiqui S, Fabbri LM, Beghe B, Rabe KF, Papi A, Brightling CE, Singh D, Kocks JWH, Franzini L, Vonk JM, Kerstjens HAM, Heijink IH, Pouwels SD, Slebos DJ, van den Berge M. Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational study. Lancet Respir Med. 2025 Nov;13(11):990-1000. doi: 10.1016/S2213-2600(25)00283-8. Epub 2025 Sep 29. |
| 38901877 | Derived | Kole TM, Muiser S, Kraft M, Siddiqui S, Fabbri LM, Rabe KF, Papi A, Brightling C, Singh D, van der Molen T, Nawijn MC, Kerstjens HAM, van den Berge M. Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study. BMJ Open Respir Res. 2024 Jun 19;11(1):e002316. doi: 10.1136/bmjresp-2024-002316. |
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided